Telix Pharmaceuticals Limited
TLX
$17.60
$0.301.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 55.10% | 64.95% | 76.27% | 124.15% | 206.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.10% | 64.95% | 76.27% | 124.15% | 206.85% |
| Cost of Revenue | 50.44% | 60.98% | 73.29% | 116.14% | 196.70% |
| Gross Profit | 58.12% | 67.53% | 78.20% | 129.37% | 213.83% |
| SG&A Expenses | 65.80% | 70.61% | 74.45% | 54.02% | 35.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.64% | -131.01% | -150.19% | -182.59% | -70.00% |
| Total Operating Expenses | 54.81% | 61.24% | 67.25% | 58.92% | 85.20% |
| Operating Income | 57.57% | 105.58% | 228.05% | 268.98% | 164.89% |
| Income Before Tax | 2,064.96% | 380.22% | 221.42% | 148.69% | 102.45% |
| Income Tax Expenses | 397.86% | 34.52% | -87.80% | -6.00% | -136.93% |
| Earnings from Continuing Operations | 974.90% | 329.81% | 200.99% | 138.74% | 104.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 974.90% | 329.81% | 200.99% | 138.74% | 104.18% |
| EBIT | 57.57% | 105.58% | 228.05% | 268.98% | 164.89% |
| EBITDA | 52.82% | 93.67% | 185.23% | 296.97% | 176.12% |
| EPS Basic | 983.70% | 319.82% | 198.03% | 137.30% | 103.88% |
| Normalized Basic EPS | 89.02% | 177.59% | 713.25% | 214.57% | 141.80% |
| EPS Diluted | 1,069.51% | 310.02% | 195.17% | 136.19% | 103.46% |
| Normalized Diluted EPS | 83.57% | 171.08% | 690.36% | 213.09% | 141.38% |
| Average Basic Shares Outstanding | 3.77% | 3.24% | 2.70% | 2.52% | 2.75% |
| Average Diluted Shares Outstanding | 6.63% | 6.27% | 5.90% | 4.59% | 4.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
